Collegium Pharma (COLL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 63,960 | 172,894 | 228,610 | 238,947 | 258,532 |
| Marketable Securities | 80,997 | 98,737 | 89,438 | 71,601 | 46,033 |
| Receivables | 228,456 | 183,855 | 174,693 | 179,525 | 181,851 |
| Inventories | 38,032 | 27,862 | 31,276 | 32,332 | 34,125 |
| TOTAL | $443,810 | $510,198 | $539,260 | $537,600 | $537,086 |
| Non-Current Assets | |||||
| PPE Net | 14,614 | 14,976 | 15,457 | 15,983 | 16,645 |
| Intangibles | 1,092,834 | 486,533 | 521,048 | 555,565 | 590,079 |
| Other Non-Current Assets | 83,896 | 41,681 | 38,485 | 34,160 | 33,768 |
| TOTAL | $1,191,344 | $543,190 | $574,990 | $605,708 | $640,492 |
| Total Assets | $1,635,154 | $1,053,388 | $1,114,250 | $1,143,308 | $1,177,578 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 64,583 | 183,333 | 183,333 | 183,333 | 183,333 |
| Accounts payable and accrued liabilities | 3,142 | 2,412 | 6,020 | 8,692 | 3,653 |
| Accrued Expenses | 361,474 | 274,934 | 256,070 | 264,902 | 276,663 |
| Other current liabilities | 28,956 | N/A | N/A | N/A | N/A |
| TOTAL | $459,426 | $461,717 | $446,436 | $457,915 | $464,612 |
| Non-Current Liabilities | |||||
| Long Term Debt | 565,716 | 132,845 | 177,360 | 221,713 | 265,886 |
| Other Non-Current Liabilities | 365,733 | 242,243 | 268,285 | 268,249 | 268,207 |
| TOTAL | $941,449 | $375,088 | $445,645 | $489,962 | $534,093 |
| Total Liabilities | $1,400,875 | $836,805 | $892,081 | $947,877 | $998,705 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 32,250 | 32,214 | 32,715 | 31,960 | 32,611 |
| Common Shares | 40 | 40 | 39 | 38 | 38 |
| Retained earnings | -176,535 | -185,870 | -205,476 | -233,189 | -265,129 |
| Other shareholders' equity | 12 | -563 | -505 | -367 | 24 |
| TOTAL | $234,279 | $216,583 | $222,169 | $195,431 | $178,873 |
| Total Liabilities And Equity | $1,635,154 | $1,053,388 | $1,114,250 | $1,143,308 | $1,177,578 |